This section will focus on studies evaluating efficacy of IL-5-targeted treatment in systemic HES (namely, idiopathic and lymphocytic variants) and EGPA (Table 3). The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.